Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill

Executive Summary

Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

You may also be interested in...



COVID-19 Or Co-Pays: Which Is More Complex?

One of many unresolved issues for the next round of COVID-19 response legislation in the US is whether and how to assure that an eventual vaccine is affordable for all Americans. The House wants to make it free to everyone – which is a lot harder than it sounds.

House Bill Would Eliminate COVID-19 Drug, Vaccine Cost-Sharing For Most Americans

After failing to get many co-pay waivers in earlier coronavirus relief legislation, the House tries again – with an even bolder ask covering more Americans. The bill would also speed up CDC’s guidance on vaccines and ensure Medicare Part D plans cover all coronavirus treatments. But its not clear whether the Senate will get on board.

Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?

The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel